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Abstract
Background: Heart rate (HR) is an important risk factor in coronary artery disease (CAD). 
However, there is little contemporary data on HR and the use of HR-lowering medications, 
particularly beta-blockers, among patients with stable CAD in routine clinical practice.
Aim: To describe HR in the Polish population of the CLARIFY registry, overall and in 
relation to beta-blocker use, and to assess the determinants of HR.
Methods and results: CLARIFY is an international, prospective, observational, longitudinal 
registry of outpatients with stable CAD, defined as either prior myocardial infarction or 
revascularisation procedure, or evidence of coronary stenosis of at least 50%, or chest pain 
associated with proven myocardial ischaemia. A total of 33,438 patients from 45 countries in 
Europe, the Americas, Africa, the Middle East, and Asia/Pacific were enrolled between 
November 2009 and July 2010. In Poland, 1,004 patients were enrolled between February and
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June 2010, which was the largest population among countries from Eastern Europe. Most 
patients were men (72.8%). Mean ± SD age was 62.1 ± 9.1 years. HR determined by pulse 
was 69.3 ± 9.4 bpm and by electrocardiogram was 68.2 ± 10.6 bpm. Beta-blockers were used 
in 89.9% of patients. Resting HR ≥ 70 bpm was noted in 49.3% of all patients and in 48.6% of
patients on beta-blockers. Resting HR ≥ 70 bpm was significantly more frequent among 
younger patients, and in those with diabetes, those being treated for arterial hypertension, and 
who lacked regular physical activity. Patients with HR ≥ 70 bpm at rest had more frequent 
symptoms of angina and more frequently needed hospitalisation due to heart failure.
Conclusions: Despite a very high rate of beta-blocker use, almost 50% of patients with stable 
CAD had a resting HR ≥ 70 bpm, which was associated with more frequent angina and 
ischaemia. Further HR lowering is possible in many patients with CAD. Whether or not this 
will improve symptoms and outcomes is under investigation.
Key words: heart rate, coronary artery disease, beta-blockers
Streszczenie
Wstęp: Częstotliwość rytmu serca (HR) jest ważnym czynnikiem ryzyka u pacjentów ze 
stabilną chorobą wieńcową (CAD). Wciąż mało jest aktualnych danych na temat HR i 
farmakoterapii za pomocą leków obniżających HR (w tym beta-adrenolityków) w codziennej 
praktyce klinicznej u pacjentów ze stabilną CAD. 
Cel: Celem niniejszego artykułu jest omówienie wyjściowej charakterystyki polskiej 
populacji rejestru CLARIFY, również w odniesieniu do leczenia beta-adrenolitykami oraz 
ocena czynników wpływających na HR.
Metody i wyniki: CLARIFY to międzynarodowe, prospektywne, badanie obserwacyjne 
dotyczące ambulatoryjnych pacjentów ze stabilną CAD. Kryteriami włączenia były: wywiad 
zawału serca, przebyte leczenie rewaskularyzacyjne, stwierdzenie w koronarografii co 
najmniej 50% zwężeń w tętnicach wieńcowych lub występowanie dolegliwości 
stenokardialnych z udowodnionym niedokrwieniem w testach prowokacyjnych. Pomiędzy 
listopadem 2009 r. a lipcem 2010 r. do badania włączono 33 438 pacjentów z 45 krajów 
Europy, Ameryki Północnej i Południowej, Afryki, Azji, Australii i Oceanii. W Polsce między 
lutym a czerwcem włączono 1004 osób, co stanowi największą grupę chorych wśród krajów 
tzw. Europy Wschodniej. W większości byli to mężczyźni (72.8%). Średni ± SD wiek wynosił
62,1 ± 9,1 roku, średnia HR oceniana za pomocą fali tętna wynosiła 69,3 ± 9,4, a za pomocą 
elektrokardiogramu 68,2 ± 10,6 uderzeń na minutę. Beta-adrenolityki były stosowane u 
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89,9% pacjentów. Spoczynkową HR ≥ 70/min stwierdzono u 49,3% wszystkich chorych i u 
48,6% pacjentów leczonych beta-adrenolitykami. Spoczynkowa HR ≥ 70/min istotnie częściej
występowała u młodszych chorych, z cukrzycą, leczonym nadciśnieniem tętniczym i 
niestosujących regularnie wysiłku fizycznego. U chorych ze spoczynkową HR ≥ 70/min 
częściej występowały objawy dławicowe i częściej wymagali hospitalizacji z powodu 
niewydolności serca.
Wnioski: Pomimo bardzo wysokiego odsetka pacjentów ze stabilną CAD leczonych beta-
adrenolitykami nadal u niemal 50% osób spoczynkowa HR wynosi ≥ 70/min, co wiąże się z 
częstszym występowaniem objawów dławicowych i niedokrwieniem mięśnia sercowego. U 
wielu z tych chorych można w istotny sposób zwolnić spoczynkową HR. Odpowiedź na 
pytanie, czy takie postępowanie będzie się wiązało z poprawą rokowania i zmniejszeniem 
dolegliwości, wymaga przeprowadzenia dalszych badań.
Słowa kluczowe: częstotliwość rytmu serca, stabilna choroba wieńcowa, beta-adrenolityki
INTRODUCTION
Coronary artery disease (CAD) is a leading cause of death in Poland and worldwide [1, 2]. It 
is estimated that of each 1,000 inhabitants of European countries, 20–40 suffer from stable 
CAD. We still lack data on clinical characteristics and management of outpatients with stable 
CAD. Most contemporary data comes from studies evaluating patients from Europe or North 
America with acute coronary syndromes or who are treated with percutaneous coronary 
intervention (PCI).
The prospective observational Longitudinal Registry of patients with stable coronary 
artery disease (CLARIFY) study is a registry created to improve our knowledge about patients
with stable CAD from a global perspective [3]. The main issue was to define the demographic
characteristics, clinical profiles, the implementation of the guidelines, and the long-term 
prognostic determinants in this group of patients. The very same objectives were pursued in 
the Polish population. 
Heart rate (HR) is one of the determinants of myocardial ischaemia and a well-
established prognostic factor in patients with CAD [4–7] or congestive heart failure [8]. HR is
also a predictor of the future occurrence of an acute coronary event [4, 9]. The clinical 
benefits of HR-lowering agents, especially beta-blockers, are well known, particularly in 
patients with a history of myocardial infarction (MI) [10].
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Beta-blockers have an impact on several mechanisms of the heart’s work, and they are 
not only HR lowering agents. However, recent data from the BEAUTIFUL trial indicates that 
decreasing HR using a pure HR-lowering agent, ivabradine, is associated with the prevention 
of angina, reduction of myocardial ischaemia, and may prevent acute coronary events [11, 
12]. Yet little is known about the HR actually achieved in real clinical practice, including in 
patients treated with HR-lowering agents.
The main objective of this analysis was to describe the Polish population of the 
CLARIFY registry, particularly the HR actually achieved, determinants of higher HR, the 
relationship between HR and the use of beta-blockers, and the incidence of important clinical 
symptoms like angina or heart failure.
METHODS
CLARIFY is an ongoing, international, prospective, observational, longitudinal cohort study 
in stable CAD outpatients with a five-year follow-up. Patients were enrolled in 45 countries in
Africa, Asia, Australia, Europe, and North and South America. Patients are treated according 
to usual clinical practice, with no specific tests or therapies defined by the study protocol. In 
Eastern Europe, 3,009 patients were enrolled in nine countries, at 229 study sites.
Study population 
The inclusion criterion was a history of stable CAD, defined as at least one of the following: 
documented MI or coronary revascularisation (PCI or coronary artery bypass graft surgery 
[CABG]) > three months earlier, coronary stenosis > 50% in coronary angiography or chest 
pain with proven myocardial ischaemia in noninvasive stress tests (electrocardiography 
[ECG], echocardiography, or myocardial imaging). The exclusion criteria were hospitalisation
within the last three months for cardiovascular reasons (including revascularisation), planned 
revascularisation, or conditions that may hamper participation in the five-year follow-up 
(limited co-operation or legal capacity, serious non-cardiovascular disease, limited life 
expectancy, severe cardiovascular diseases such as advanced heart failure, valve disease, or a 
history of valve repair/replacement).
Site selection
The main assumption of the study was that enrolled patients corresponded to a real 
epidemiological pattern in each participating country. The chosen physicians (cardiologists, 
internists, and primary care physicians) enrolled, over a short period of time so as to avoid 
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selection bias, 10–15 consecutive patients who met the inclusion criteria and to whom the 
exclusion criteria were not applicable. The goal was to enroll 25 (12.5–50) patients per 
1,000,000 inhabitants to ensure a balanced representation of each country. The assumed 
number of enrolled patients was exactly achieved in Poland.
Baseline evaluation and data management
Data collected at baseline included demographics, medical history, risk factors, lifestyle, and 
current symptoms. Patients were examined and HR was determined both by pulse palpation 
and most recent ECG (performed within the last six months). Blood test results (e.g. 
haemoglobin, fasting glucose, haemoglobin A1c, creatinine, cholesterol, triglycerides) and 
current chronic medical treatment (drugs taken regularly more than seven days before 
entering the study) were also recorded.
A standardised, international, electronic case report form translated into the local 
language was used for data collection. It was sent electronically to the data management 
centre where completeness, internal consistency, and accuracy were checked.
Statistical analysis
All data is collected and analysed at the Robertson Centre for Biostatistics, University of 
Glasgow, UK, which is responsible for managing the database, performing all analyses, and 
storing the data according to regulations. Baseline variables are summarised as mean and 
standard deviation (SD), or median, lower and upper quartiles for continuous data depending 
on the distribution of the data; and as counts and percentages for categorical data. Differences 
between the groups were tested using one-way analysis of variance (ANOVA), or Kruskal-
Wallis test for continuous variables, again depending on the distribution of the data, and 
Pearson’s χ2 test or Fisher’s exact test for categorical variables. A multivariable analysis of 
independent correlates of HR ≥ 70 bpm was performed using a logistic regression model. The 
cut-off value of 70 bpm was selected based on the results of several studies showing that this 
is an important prognostic threshold across a variety of patient populations [11, 13–16]. All 
clinical baseline variables were considered for entry into the model as predictors of HR ≥ 70 
bpm and univariate models for each were produced. The use of HR-lowering medications was
considered to be the most important treatment variable, and so this was the only treatment 
predictor entered in the analyses. The multivariable model was then built using a stepwise 
selection method applied to the remaining significant univariate predictors, with the use of 
HR-lowering medications being forced into the model.
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RESULTS
A total of 1,004 patients were screened and then enrolled by 79 investigators in Poland 
between 25 February and 29 June 2010. This was the largest population of any of the Eastern 
European countries. All the patients were available for analysis.
Mean ± SD age was 62.1 ± 9.1 years and most of the patients were men (72.8%). The 
median time since first diagnosis of CAD was six years (IQR 2–10 years). 66.8% of patients 
had a history of MI, 60.6% had a PCI, and 25.7% a CABG. 30.3% of the patients had angina 
symptoms. Coronary angiography had been performed in 81% of the patients and 73.8% had 
undergone noninvasive testing for ischaemia. HR measured by pulse palpation (mean [SD] 
HR 69.3 [9.4] bpm) was highly correlated with HR measured by ECG (68.2 [10.6] bpm) 
(Pearson correlation coefficient 0.79, p < 0.0001).
Patients were divided into three categories according to baseline pulse palpation HR at
rest: ≤ 60 bpm (218, 21.7%), 61–69 bpm (291, 29.0%), and ≥ 70 bpm (495, 49.3%). Resting 
HR ≥ 70 bpm was significantly more frequent among younger patients, in those with a history
of diabetes, treated arterial hypertension, no or light regular physical activity, and higher body
mass index. Patients with a higher HR had more frequent angina symptoms, lower left 
ventricular ejection fraction, and more often were admitted to hospital due to heart failure. 
Additionally, they less frequently had stenosis > 50% of the right coronary artery, or a sinus 
rhythm identified in ECG, and less frequently underwent noninvasive testing for myocardial 
ischaemia. They also had higher blood pressure (both systolic and diastolic). Patients with low
HR (≤ 60 bpm) had lower fasting triglycerides and higher high-density lipoprotein. There was
no significant association between HR and gender, history of MI, invasive treatment (CABG 
or PCI), or time since the first CAD diagnosis. The most important characteristics of clinical 
and laboratory parameters according to HR are shown in Table 1.
Overall, 89.9% of patients were treated with beta-blockers (any one at any dose), 
95.1% with acetylsalicylic acid, 12.7% with thienopyridines, and 95.8% with lipid-lowering 
agents. Other HR-lowering agents like ivabradine (4.5%), diltiazem or verapamil (4.9%), 
amiodarone/dronedarone (0.9%), and digoxin or derivatives (0.9%) were used less often. 
Patients treated with ivabradine had higher HR, but there were no significant differences in 
the proportions of higher HR in subgroups treated with other HR-lowering agents (including 
beta-blockers). Additionally, patients with higher HR were treated more often with oral 
anticoagulants, antidiabetic agents, and proton pump inhibitors. The median number of HR-
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lowering agents was one in the whole population and in each HR subgroup. The most 
important medications according to HR are shown in Table 2.
The entire population was also divided into two groups according to treatment with 
beta-blockers. Men, patients with a history of treated hypertension, prior MI, or CABG were 
significantly more frequently treated with beta-blockers, in contrast to patients with peripheral
artery disease, carotid disease, and asthma/chronic obstructive pulmonary disease, where beta-
blockers were used significantly less often. 
Patients treated with beta-blockers had higher body mass index, greater waist 
circumference, and lower left ventricular ejection fraction. Mean (SD) HR assessed by 
palpation or ECG was lower in the beta-blocker group (69.1 [9.1] vs. 71.4 [11.5] and 67.9 
[10.3] vs. 70.7 [12.6], respectively), but there was no significant difference in the proportion 
of patients with HR ≥ 70 bpm (48.6% vs. 55.4%, p = 0.19) despite the use of these agents. 
Also there were no differences in the usage of beta-blocker according to age or history of PCI 
(Table 3).
Patients treated with beta-blockers more frequently received acetylsalicylic acid and 
angiotensin-converting enzyme inhibitors, in contrast to ivabradine and verapamil or 
diltiazem, which were used less often (Table 3).
Multivariable logistic regression analysis indicated that elevated systolic blood 
pressure, full reimbursement of cardiovascular agents and diabetes were significantly 
associated with higher HR, in contrast to increasing physical activity, noninvasive testing for 
myocardial ischaemia, or stenosis > 50% of the right coronary artery, which had a protective 
effect. Social factors were independent correlates of HR as well. Patients unable to work had a
higher HR than those who were employed full time (Table 4.). Also it turns out that not taking
HR-lowering agents is not significantly associated with a higher HR after adjustment for these
other variables.
DISCUSSION
The CLARIFY registry offers a unique opportunity for very detailed information on the 
determinants of higher HR in stable CAD patients in Poland and also all over the world. 
Despite the proven prognostic importance of HR and the threshold ≥ 70 bpm in patients with 
CAD or heart failure [4–9], these determinants are still poorly defined.
Overall, almost half of patients with stable CAD had resting HR ≥ 70 bpm and only 
about 20% had HR ≤ 60 bpm, which is the guidelines-recommended target for HR in patients 
with angina on beta-blockers [17]. Due to the very high beta-blocker use (about 90%), similar 
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to that seen in a previous Polish RECENT study [18], the proportions of beta-blocker-treated 
patients in various HR categories were nearly the same. These findings are also consistent 
with results from the EuroHeart Survey on angina in which 19% of patients had HR ≤ 62 bpm
[19] and with the overall results of the CLARIFY registry where half of the population had an
HR ≥ 70 bpm and only 28% of patients had HR ≤60 bpm [20]. 
In our study, multivariable analysis revealed some independent predictors of higher 
HR. Diabetes, higher systolic blood pressure and social factors such as inability to work were 
correlated with a higher risk of HR ≥ 70 bpm. On the other hand, performing noninvasive 
testing and increased physical activity had a protective influence. The relationship between 
stenosis > 50% of the right coronary artery, reimbursement of cardiovascular agents and 
higher HR seems to be rather accidental. Not taking HR-lowering agents appeared not to be 
significantly associated with risk of higher HR after adjustment for these other variables. 
These findings have very important clinical implications. Despite treatment with HR-
lowering agents, especially beta-blockers, the proportion of patients with elevated HR remains
high. According to European and American guidelines for the management of stable angina, 
beta-blockers are the first-line anti-anginal therapy [21, 22]. One of the factors that may limit 
the use of beta-blockers is low blood pressure, but the data shows that patients with HR ≥ 70 
bpm had generally higher blood pressure. It seems that there is a potential for increasing and 
adjusting the dose of beta-blockers or adding the second agent (ivabradine) to achieve better 
HR control. 
There are other potential limitations of proper treatment with beta-blockers: 
inadequate knowledge of evidence or treatment targets by clinicians [23], comorbidities that 
could be a contraindication or decreased tolerance to beta-blockers, side effects of beta-
blockers, or access to medical care and reimbursement. 
However, there is a discussion as to whether other HR-lowering agents could provide 
benefits similar to those of beta-blockers. In stable CAD there is no difference between beta-
blockers and calcium antagonists in reducing the rate of cardiac death or MI [24]. Ivabradine, 
the pure HR-lowering drug, did not improve overall clinical outcome [11], but subgroup 
analysis of patients with HR ≥ 70 bpm showed that ivabradine reduced the incidence of 
coronary events [7, 12]. The ongoing SIGNIFY trial may answer the question as to whether 
ivabradine, a pure HR-lowering agent, can improve clinical outcomes in patients with CAD 
but without heart failure [25].
Higher HR was also correlated with lack of, or low, physical activity. Thus efforts to 
encourage lifestyle changes seem to be another safe and effective way of reducing HR.
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CONCLUSIONS
It is worth reiterating that, despite a very high rate of treatment with beta-blockers, about half 
of the stable CAD patients in Poland still have HR ≥ 70 bpm. Patients with higher HR more 
often have symptoms of angina and more frequently need hospitalisation due to heart failure. 
It seems that there is a possibility of further lowering the HR in many patients with stable 
CAD. Whether or not this will improve symptoms and outcomes is under investigation.
CLARIFY Registry Investigators in Poland
Krzysztof Adamaszek (Grudziądz); Dorota Adamczyk-Kot (Jędrzejów); Agata Adamkiewicz-
Piejko (Kraków); Joanna Banach (Bydgoszcz); Piotr Błaszczak (Lublin); Paweł Bogdański 
(Poznań); Piotr Brodzicki (Kraków); Wiesław Bryl (Kościan); Inga Chlewicka (Warszawa); 
Robert Chyrek (Poznań); Ewa Cisowska-Drozd (Mielec); Jerzy Cygler (Giżycko); Bogusław 
Demianiuk (Bielsk Podlaski); Małgorzata Dereń (Leżajsk); Jakub Drozd (Lublin); Anna 
Drzewiecka (Czeladź); Renata Duchowska (Wałbrzych); Mirosław Fic (Jelenia Góra); Anna 
Frankiewicz (Gdańsk); Romana Furtak (Rzeszów); Waldemar Gadziński (Bydgoszcz); Alicja 
Gałuszka-Bilińska (Ruda Śląska); Grażyna Glanowska (Gliwice); Marcin Gruchała (Gdańsk); 
Anna Jankowska (Lublin); Lucyna Jankowska (Szczecin); Piotr Jarmużek (Międzyrzecz); 
Grzegorz Jarosiński (Katowice); Olga Jerzykowska (Poznań); Monika Jeżewska (Toruń); 
Rafał Kacorzyk (Przybysławice); Ewa Kaźmierczak (Poznań); Wojciech Kępa (Skarżysko-
Kamienna); Lilianna Kisiel (Augustów); Urszula Kossowska (Ełk); Andrzej Królak 
(Świdnica); Karolina Królicka (Opole); Waldemar Kulig (Mielec); Lucyna Lenartowska 
(Wrocław); Jacek Lorenc (Krzeszowice); Elżbieta Łotocka (Lublin); Tomasz Ługowski 
(Bydgoszcz); Maryla Maćków (Legnica); Maciej Maliszewski (Ostrowiec Świętokrzyski); 
Gabriela Matuszewska (Zabrze); Katarzyna Modzelewska (Bielsk Podlaski); Tatiana 
Mularek-Kubzdela (Poznań); Iwona Nikodemska (Dobra); Elżbieta Nowicka (Wrocław); 
Alicja Nowowiejska-Wiewióra (Zabrze); Artur Olszewski (Bartoszyce); Krzysztof 
Orzechowski (Świdnik); Tomasz Pitsch (Knurów); Beata Poprawa (Tarnowskie Góry); 
Andrzej Prokop (Sosnowiec); Aldona Regulska (Krosno); Roman Sadłowski (Bytów); Marek 
Sidor (Lubartów); Benwenuta Sikorska-Buczkowska (Gniezno); Ilona Skoczylas 
(Pyskowice); Joanna Słaboszewska (Wejherowo); Dorota Sobczyk (Kraków); Marek 
Sołtysiak (Lubin); Tomasz Stasiuk (Kwidzyń); Witold Streb (Rybnik); Jerzy Sudnik 
(Sokółka); Piotr Szałkowski (Gdańsk); Aleksander Szpak (Brzeg); Marek Szulc (Morąg); 
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Paweł Turek (Kraków); Grzegorz Walawski (Leżajsk); Jolanta Walczewska (Kraków); 
Magdalena Węglarz (Bydgoszcz); Małgorzata Winter (Wrocław); Mariola Wrębiak-Trznadel 
(Dąbrowa Górnicza); Ryszard Wysocki (Ostrów Wielkopolski); Dorota Zalewska (Skała); 
Joanna Zdrojewska (Szczecin); Rafał Zimoląg (Nowa Sól)
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Table 1. The most significant characteristics of the Polish population classified according to resting heart rate 
Parameter
No. of 
patients Population Total (n = 1,004)
HR ≤ 60 
bpm (n = 
218)
HR 61–
69 bpm 
(n = 291)
HR ≥ 70 
bpm (n = 
495) P
Age 1,004 Mean (SD) 62.1 (9.1) 63.5 (9.7) 61.9 (8.9) 61.63 (8.9) 0.0368
Gender 1,004 Male 731 (72.8) 157 (72.0) 216 
(74.2)
358 (72.3) 0.8092
Body mass 
index
1,004 Median [Q1, Q3] 28.4 [25.9, 30.9] 27.9 [25.7,
30.4]
28.0 
[25.9, 
30.7]
28.7 [26.1, 
31.4]
0.0283
Time since first
CAD diagnosis 
[years]
1,004 Median [Q1, Q3] 6 [2, 10] 5 [2, 11] 6 [2, 12] 5 [2, 10] 0.3399
Myocardial 
infarction
1,004 N (%) 671 (66.8) 133 (61.0) 200 
(68.7)
338 (68.3) 0.1179
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PCI 1,004 N (%) 608 (60. 6) 134 (61.5) 179 
(61.5)
295 (59.6) 0.8277
CABG 1,004 N (%) 258 (25.7) 68 (31.2) 68 (23.4) 122 (24.6) 0.1022
Hospitalisation 
for CHF
1,004 N (%) 44 (4.4) 4 (1.8) 11 (3.8) 29 (5.9) 0.0450
Treated 
hypertension
1,004 N (%) 789 (78.6) 158 (72.5) 226 
(77.7)
405 (81.8) 0.0178
Diabetes 1,004 N (%) 279 (27.8) 49 (22.5) 70 (24.1) 160 (32.3) 0.0062
Physical 
activity
1,004 No physical 
activity weekly
106 (10. 6) 21 (9.6) 24 (8.2) 61 (12.3) 0.0011
Light physical 
activity 
489 (48.7) 87 (39.9) 140 
(48.1)
262 (52.9)
At least 20 min 
of physical 
activity once or 
twice a week
207 (20.6) 48 (22.0) 70 (24.1) 89 (18.0)
At least 20 min 
of physical 
activity at least 
three times a 
week
202 (20.1) 62 (28.4) 57 (19.6) 83 (16.8)
Any angina 1,004 N (%) 304 (30.3) 63 (28.9) 68 (23.4) 173 (34.9) 0.0026
Angina and 
CCS Class
1,004 No angina 700 (69.7) 155 (71.1) 223 
(76.6)
322 (65.1) 0.0453
Angina CCS 
Class I
99 (9.9) 19 (8.7) 24 (8.2) 56 (11.3)
Angina CCS 
Class II
170 (16.9) 35 (16.1) 38 (13.1) 97 (19.6)
Angina CCS 
Class III
35 (3.5) 9 (4.1) 6 (2.1) 20 (4.0)
HDL [mmol/L] 692 Median [Q1, Q3] 1.2 [1.0, 1.4] 1.3 [1.1, 
1.5]
1.2 [1.0, 
1.4]
1.2 [1.0, 
1.4]
0.0411
Fasting 
triglycerides 
[mmol/L]
733 Median [Q1, Q3] 1.4 [1.1, 1.9] 1.2 [0.9, 
1.6]
1.5 [1.0, 
1.9]
1.5 [1.1, 
2.0]
< 
0.0001
Heart rate 
(palpation)
1004 Mean (SD) 69.3 (9.4) 57.9 (3.3) 65.3 (2.1) 76.7 (7.1)
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ECG heart rate 
[bpm]
775 Mean (SD) 68.2 (10.6) 58.7 (6.3) 64.6 (6.4) 75.1 (9.6)
SBP [mm Hg] 1,004 Mean (SD) 132.6 (15.7) 130.2 
(14.9)
130.9 
(15.5)
134.7 
(15.9)
0.0002
DBP [mm Hg] 1,004 Mean (SD) 79.6 (9.5) 77.2 (9.6) 79.3 (8.6) 80.8 (9.7) < 
0.0001
LVEF [%] 713 Mean (SD) 52.9 (9.6) 53.5 (8.7) 54.2 (9.2) 51.8 (10.1) 0.0104
RCA stenosis >
50%
1,004 N (%) 438 (43.6) 111 (50.9) 135 
(46.4)
192 (38.8) 0.0057
Non invasive 
test for 
myocardial 
ischaemia
1,004 N (%) 741 (73.8) 163 (74.8) 233 
(80.1)
345 (69.7) 0.0057
ECG rhythm 775 Sinus rhythm 740 (95.5) 179 (96.8) 218 
(98.2)
343 (93.2) 0.0124
AF/atrial flutter 9 (1.2) 0 (0) 0 (0) 9 (2.4)
Paced rhythm 26 (3.4) 6 (3.2) 4 (1.8) 16 (4.3)
HR — heart rate; CAD — coronary artery disease; PCI — percutaneous coronary intervention; CABG — 
coronary artery bypass grafting; ECG — electrocardiogram; CHF — congestive heart failure; CCS — Canadian 
Cardiovascular Society; HDL — high density lipoprotein; SBP — systolic blood pressure; DBP — diastolic 
blood pressure; LVEF — left ventricular ejection fraction; RCA — right coronary artery; AF — atrial fibrillation
Table 2. Pharmacotherapy of the Polish population classified according to resting heart rate
Parameter
No. of 
patien
ts Population
Total (n =
1,004)
HR ≤ 60 
bpm (n = 
218)
HR 61–69
bpm (n = 
291)
HR ≥ 70 
bpm (n = 
495) P
Aspirin 1,004 N (%) 955 (95.1) 208 (95.4) 279 (95.9) 468 (94.5) 0.6870
Thienopyridine 1,004 N (%) 128 (12.7) 23 (10.6) 42 (14.4) 63 (12.7) 0.4297
Oral anticoagulants 1,004 N (%) 64 (6.4) 11 (5.0) 9 (3.1) 44 (8.9) 0.0038
Beta-blockers 1,004 N (%) 903 (89.9) 200 (91.7) 264 (90.7) 439 (88.7) 0.3987
Ivabradine 1,004 N (%) 45 (4.5) 3 (1.4) 12 (4.1) 30 (6.1) 0.0194
Calcium antagonists 1,004 N (%) 268 (26.7) 49 (22.5) 71 (24.4) 148 (29.9) 0.0685
Verapamil or diltiazem 1,004 N (%) 49 (4.9) 5 (2.3) 15 (5.2) 29 (5.9) 0.1219
Angiotensin-converting 
enzyme inhibitors
1,004 N (%) 753 (75.0) 161 (73.9) 225 (77.3) 367 (74.1) 0.5536
Angiotensin II receptor 
blockers
1,004 N (%) 175 (17.4) 37 (17.0) 48 (16.5) 90 (18.2) 0.8175
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Lipid-lowering drugs 1,004 N (%) 962 (95.8) 208 (95.4) 283 (97.3) 471 (95.2) 0.3450
Long-acting nitrates 1,004 N (%) 139 (13.8) 29 (13.3) 36 (12.4) 74 (14.9) 0.5799
Diuretics 1,004 N (%) 388 (38.6) 78 (35.8) 103 (35.4) 207 (41.8) 0.1254
Digoxin and derivatives 1,004 N (%) 9 (0.9) 1 (0.5) 2 (0.7) 6 (1.2) 0.7478
Amiodarone/dronedarone 1,004 N (%) 9 (0.9) 3 (1.4) 3 (1.0) 3 (0.6) 0.5600
Antidiabetic agents 1,004 N (%) 238 (23.7) 40 (18.3) 60 (20.6) 138 (27.9) 0.0076
Proton pump inhibitors 1,004 N (%) 280 (27.9) 59 (27.1) 67 (23.0) 154 (31.1) 0.0485
Number of heart rate 
lowering agents
1,004 Median [Q1, Q3] 1 [1, 1] 1 [1, 1] 1  [1, 1] 1 [1, 1] 0.2360
Table 3. The most important characteristics and medications of the Polish population classified according to 
beta-blocker usage
Parameter
Total 
available Population
Any BB (n = 
903)
No BB (n = 
101) P
Age 1,004 Mean (SD) 62.2 (9.0) 61.7 (9.4) 0.6022
Gender 1,004 Male 668 (74.0) 63 (62.4) 0.0130
Body mass index 1,004 Median [Q1, Q3] 28.4 [26.0, 
31.1]
27.1 [24.7, 
30.0]
0.0012
Waist circumference [cm] 1,004 Median [Q1, Q3] 97 [90, 104] 94 [84, 102] 0.0369
Heart rate (palpation) 1,004 Mean (SD) 69.1 (9.1) 71.4 (11.5) 0.0218
Heart rate (ECG) 775 Mean (SD) 67.9 (10.3) 70.7 (12.6) 0.0260
Heart rate [bpm] 1,004 Hart rate (palpation)
≥ 70 bpm
439 (48.6) 56 (55.4) 0.1929
Left ventricular ejection fraction (%) 713 Mean (SD) 52.68 (9.6) 55.33 (8.5) 0.0358
Treated hypertension 1,004 N (%) 720 (79.7) 69 (68.3) 0.0080
Peripheral arterial disease 1,004 N (%) 91 (10.1) 20 (19.8) 0.0031
Myocardial infarction 1,004 N (%) 615 (68.1) 56 (55.4) 0.0104
Percutaneous coronary intervention 1,004 N (%) 549 (60.8) 59 (58.4) 0.6423
Coronary artery bypass grafting 1,004 N (%) 243 (26.9) 15 (14.9) 0.0085
Carotid disease 1,004 N (%) 33 (3.7) 9 (8.9) 0.0299
Asthma/COPD 1,004 N (%) 47 (5.2) 11 (10.9) 0.0202
Haemoglobin A1c [%] 74 Mean (SD) 6.83 (1.1) 8.23 (1.4) 0.0034
Creatinine [µmol/L] 587 Median [Q1, Q3] 87 [76, 97] 80 [68, 93] 0.0499
High density lipoprotein [mmol/L] 692 Median [Q1, Q3] 1.2 [1.0, 1.4] 1.3 [1.1, 1.6] 0.0036
Low density lipoprotein [mmol/L] 689 Median [Q1, Q3] 2.6 [2.0, 3.2] 2.8 [2.2, 3.8] 0.0264
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Parameter
Total 
available Population
Any BB (n = 
903)
No BB (n = 
101) P
Coronary territories with stenosis > 
50%: LAD
1,004 N (%) 505 (55.9) 37 (36.6) 0.0002
Coronary angiography not done 1,004 N (%) 162 (17.9) 29 (28.7) 0.0089
Aspirin 1,004 N (%) 865 (95.8) 90 (89.1) 0.0069
Symptoms indicative of intolerance or 
contraindication to beta-blockers
1,004 N (%) 74 (8.2) 58 (57.4) < 
0.0001
Ivabradine 1,004 N (%) 28 (3.1) 17 (16.8) < 
0.0001
Verapamil or diltiazem 1,004 N (%) 25 (2.8) 24 (23.8) < 
0.0001
ACE inhibitors 1,004 N (%) 687 (76.1) 66 (65.3) 0.0182
BB —beta-blockers; ECG — electrocardiography; COPD — chronic obstructive pulmonary disease; LAD — 
left anterior descending artery; ACE — angiotensin-converting enzyme
Table 4. Multivariable logistic regression results from stepwise model using the patients in Poland. All 
significant variables associated with an elevated heart rate (≥ 70 bpm) and forcing heart rate reducing drugs into 
the model
Variable Level
Odds ratio (95% 
confidence interval)
Pr > Chi-
square
Systolic blood pressure [per 10 mm Hg] 1.2 (1.1, 1.3) 0.0004
Employment Employed part-time 0.8 (0.4, 1.3) 0.0007
Employment Unable to work 1.7 (1.0, 2.6)
Employment Unemployed 3.1 (0.9, 10.9)
Employment Retired 0.9 (0.6, 1.2)
Employment Other 2.4 (1.1, 5.3)
Diabetes Yes 1.5 (1.1, 2.0) 0.0057
Physical activity No physical activity weekly 1.0 (0.6, 1.5) 0.0272
Physical activity At least 20 min vigorous physical 
activity once or twice a week
0.7 (0.5, 1.0)
Physical activity At least 20 min vigorous activity at 
least three times a week
0.6 (0.4, 0.9)
Right coronary artery stenosis > 50% Yes 0.7 (0.5, 0.9) 0.0030
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Variable Level
Odds ratio (95% 
confidence interval)
Pr > Chi-
square
Non invasive test performed Yes 0.6 (0.5, 0.9) 0.0032
Reimbursement of cardiovascular agents Fully reimbursed 2.8 (1.8, 4.2) < 0.0001
Taking hart rate-lowering medications No 0.8 (0.5, 1.4) 0.4221
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